Nalmefene for treatment of alcohol dependence

Expert Opinion on Investigational Drugs

Volumn 19, Issue 11, 2010, Pages 1451-1459

  Soyka, Michael ^a,b   Rösner, Susanne ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Private Hospital Meiringen   (Switzerland)

Author keywords

alcohol; alcoholism; nalmefene; opioid antagonists; opioid receptors; therapy

Indexed keywords

ALCOHOL; NALMEFENE; NALOXONE; NALTREXONE; PLACEBO;

ALCOHOL CONSUMPTION; ALCOHOLISM; CLINICAL TRIAL; CONFUSION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INSOMNIA; LIVER TOXICITY; NAUSEA; NONHUMAN; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION;

ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NALTREXONE;

EID: 77958477291     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.522990     Document Type: Review

References (88)

1. Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:361-8
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
3. Pirkola SP, Poikolainen K, Lonnqvist JK. Currently active and remitted alcohol dependence in a nationwide adult general population-results from the Finnish Health 2000 study. Alcohol Alcohol 2006;41:315-20
4. Rehm J, Room R, van den Brink W, Jacobi F. Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol 2005;15:377-88
5. Berglund M, Thelander S, Jonsson E. Treating alcohol and drug abuse: an evidence based review. Wiley-VCH, Weinheim, Cambridge; 2003
6. Soyka M, Kranzler HR, Berglund M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry 2008;9:6-23
7. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006;111:855-76
8. Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 2008;29:109-15
9. Soyka M, Rosner S. Emerging drugs to treat alcoholism. Expert Opin Emerg Drugs 2010: published online 19 June 2010. doi:10.1517/14728214.2010.500811
10. Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008;22:11-23
11. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003;12(Suppl 1):3-11
12. Ciccocioppo R, Martin-Fardon R, Weiss F. Effect of selective blockade of mu1 or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 2002;27:391-9
13. Cowen MS, Lawrence AJ. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:1171-212
14. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 2004;4:39-50
15. HerzA. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 1997;129:99-111
16. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13:177-84
17. Oswald LM, Wand GS. Opioids and alcoholism. Physiol Behav 2004;81:339-58
18. Scherbaum N, Davids E, Gastpar M. Psychische Storungen und Verhaltensstorungen durch psychotrope Substanzen-Opiate [Mental disorders and behavioural disorders caused by psychotropic substances-opiates (authors' translation)]. In: Benkert O, Grunder G, editors, Psychiatrische pharmakotherapie. 5th edition. Springer Verlag, Berlin; 2008. p. 804-14
19. Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005;11:82-9
20. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81:429-44
21. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998;95:9608-13
22. Barr CS, Schwandt M, Lindell SG, et al. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry 2007;64:369-76
23. Bart G, Kreek MJ, Ott J, et al. Increased attributable risk related to a functional μ-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005;30:417-22
24. Gelernter J, Gueorguieva R, Kranzler HR, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 2007;31:555-63
25. Job MO, Tang A, Hall FS, et al. Mu (μ) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. Biol Psychiatry 2007;62:627-34
26. Nishizawa D, Han W, Hasegawa J, et al. Association of mu-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. Neuropsychobiology 2006;53:137-41
27. van den Wildenberg E, Wiers RW, Dessers J, et al. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 2007;31:1-10
28. Xuei X, Dick D, Flury-Wetherill L, et al. Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 2006;11:1016-24
29. McGeary JE, Monti PM, Rohsenow DJ, et al. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 2006;30:1288-96
30. Oroszi G, Anton RF, O'Malley S, et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 2009;33:383-93
31. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003;28:1546-52
32. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008;65:135-44
33. Kim SG, Kim CM, Choi SW, et al. A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 2009;201:611-18
34. Koob GF, Roberts AJ, Kieffer BL, et al. Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. Recent Dev Alcohol 2003;16:263-81
35. Dai X, Thavundayil J, Gianoulakis C. Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism. Alcohol Clin Exp Res 2005;29:1965-75
36. Marinelli PW, Bai L, Quirion R, Gianoulakis C. A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res 2005;29:1821-8
37. Marinelli PW, Lam M, Bai L, et al. A microdialysis profile of dynorphin A1-8 release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res 2006;30:982-90
38. Marinelli PW, Quirion R, Gianoulakis C. A microdialysis profile of beta-endorphin and catecholamines in the rat nucleus accumbens following alcohol administration. Psychopharmacology (Berl) 2003;169:60-7
39. Marinelli PW, Quirion R, Gianoulakis C. An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience 2004;127:777-84
40. Barson JR, Carr AJ, Soun JE, et al. Opioids in the hypothalamic paraventricular nucleus stimulate ethanol intake. Alcohol Clin Exp Res 2010;34:214-22
41. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998;18:10663-71
42. Hubbell CL, Czirr SA, Hunter GA, et al. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 1986;3:39-54
43. Hubbell CL, Abelson ML, Burkhardt CA, et al. Constant infusions of morphine and intakes of sweetened ethanol solution among rats. Alcohol 1988;5:409-15
44. Marglin SH, MacKechnie DK, Mattie ME, et al. Ethanol with small doses of morphine establishes a conditioned place preference. Alcohol 1988;5:309-13
45. Reid LD. Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages.Alcohol 1996;13:5-11
46. Belluzzi JD, Stein L. Enkephalin may mediate euphoria and drive-reduction reward. Nature 1977;266:556-8
47. Goeders NE, Lane JD, Smith JE. Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol Biochem Behav 1984;20:451-5
48. Jarjour S, Bai L, Gianoulakis C. Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcohol Clin Exp Res 2009;33:1033-43
49. Mann K. Pharmacotherapy ofalcohol dependence: a review of the clinical data. CNS Drugs 2004;18:485-504
50. Adcock RA, Thangavel A, Whitfield-Gabrieli S, et al. Reward-motivated learning: mesolimbic activation precedes memory formation. Neuron 2006;50:507-17
51. O'Malley SS, Froehlich JC. Advances in the use of naltrexone: an integration of preclinical and clinical findings. Recent Dev Alcohol 2003;16:217-45
52. Bjork K, Terasmaa A, Sun H, et al. Ethanol-induced activation of AKT and DARPP-32 in the mouse striatum mediated by opioid receptors. Addict Biol 2010;15:299-303
53. Spanagel R Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 2009;89:649-705
54. Vengeliene V, Celerier E, Chaskiel L, et al. Compulsive alcohol drinking in rodents. Addict Biol 2009;14:384-96
55. Lindholm S, Ploj K, FranckJ, Nylander I. Repeated ethanol administration induces short-and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain. Alcohol 2000;22:165-71
56. Chen F, Lawrence AJ. Effect of chronic ethanol and withdrawal on the μ-opioid receptor-and 5-hydroxytryptamine1A receptor-stimulated binding of [35S]guanosine-5 '-O-(3-thio)triphosphate in the fawn-hooded rat brain: a quantitative autoradiography study. J Pharmacol Exp Ther 2000;293:159-65
57. Turchan J, Przewlocka B, Toth G, et al. The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience 1999;91:971-7
58. Cowen MS, Lawrence AJ. Alterations in central preproenkephalin mRNA expression after chronic free-choice ethanol consumption by fawn-hooded rats. Alcohol Clin Exp Res 2001;25:1126-33
59. Przewlocka B, Turchan J, Lason W, Przewlocki R Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci Lett 1997;238:13-6
60. Rosin A, Lindholm S, Franck J, Georgieva J. Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens. Neurosci Lett 1999;275:1-4
61. Bencherif B, Wand GS, McCaul ME, et al. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 2004;55:255-62
62. Heinz A, Reimold M, Wrase J, et al. Correlation of stable elevations in striatal μ-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 2005;62:57-64
63. Soyka M, Kuefner H. Alkoholismus-Missbrauch und Abhangigkeit [Alcoholism-Abuse and dependence (Authors' translation)] Stuttgart: Thieme; 2008
64. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996;13:35-9
65. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000;22:493-503
66. O'Malley SS, Krishnan-Sarin S, Farren C, OConnor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol 2000;20:69-76
67. Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology (Berl) 2001;154:397-402
68. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999;56:719-24
69. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 1994;271:1630-7
70. Ingman K, Hagelberg N, Aalto S, et al. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005;30:2245-53
71. Dixon R, Gentile J, Hsu HB, et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 1987;27:233-9
72. Gal TJ, DiFazio CA, Dixon R Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 1986;40:537-42
73. DeHaven-Hudkins DL, Brostrom PA, Allen JT, et al. Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 1990;37:497-504
74. Bart G, Schluger JH, Borg L, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 2005;30:2254-62
75. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985;7:175-7
76. Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008;33:643-52
77. Osborn MD, Lowery JJ, Skorput AG, et al. In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci 2010;86:624-30
78. Kim S, Wagner HN Jr, Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med 1997;38:1726-31
79. Mayer P, Hollt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006;16:1-7
80. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994;18:1162-7
81. Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 2004;24:421-8
82. June HL, Grey C, Warren-Reese C, et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 1998;22:2174-85
83. Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 2004;28:1362-70
84. Drobes DJ, Anton RF, Thomas SE, Voronin K. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 2003;28:755-64
85. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007;31:1179-87
86. Arias AJ, Armeli S, Gelernter J, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 2008;32:1159-66
87. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006;163:303-12
88. Feinn R, Kranzler HR. Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? Alcohol Clin Exp Res 2005;29:983-8